Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 9, 2021Clinical Journal of the American Society of NephrologyOpen Access

Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

BPBiff F. PalmerTexas Tech UniversityDCDeborah J. CleggTexas Tech University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Palmer et al. (2021) studied this question.

synapsesocial.com/papers/69dca7c84006ebb8efe52ec6https://doi.org/10.2215/cjn.17621120
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program2015 · 326 citations
  2. 2Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature2019 · 92 citations
  3. 3Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin2012 · 877 citations
  4. 4SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System2017 · 237 citations
  5. 5Renal Handling of Ketones in Response to Sodium–Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes2017 · 181 citations